| 產品編號 | bs-2347R |
| 英文名稱 | GP1BA Rabbit pAb |
| 中文名稱 | 血小板糖蛋白GPIb（CD42b）抗體 |
| 別 名 | Antigen CD42b alpha; BSS; CD 42b; CD42b alpha; CD42b antigen; GLYCOCALICIN; Glycoprotein Ib(platelet) alpha polypeptide; Glycoprotein Ibalpha; GP Ib alpha; GP1B; CD42b; GPIb alpha; MGC34595; Platelet glycoprotein Ib alpha chain; Platelet glycoprotein Ib alpha polypeptide; Platelet membrane glycoprotein 1b alpha subunit; GP1BA_HUMAN. |
 |
Specific References (4) | bs-2347R has been referenced in 4 publications.
[IF=13.91] Ye, Buqing, et al. "Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation." The Journal of Experimental Medicine (2014): jem-20141123. Mouse.
[IF=11.413] Wenhui Tao. et al. Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes. Acta Pharm Sin B. 2021 Aug;: WB ; Mouse.
[IF=9.89] Hopp et al. Targeting coagulation factor XII as a novel therapeutic option in brain trauma. (2016) Ann.Neuro. 79:970-82 WB,IF ; Mouse.
[IF=6.419] Qi-Rui Li. et al. Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery. Drug Deliv. 2022;29(1):937-949 IHC ; Mouse.
|
| 研究領域 | 心血管 細胞生物 免疫學 細胞粘附分子 細胞表面分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號 | |
| 交叉反應 | Mouse (predicted: Human,Rat) |
| 產品應用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 67 kDa |
| 檢測分子量 | 145 |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human GP1BA/CD42b: 201-300/626 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
Glycoprotein Ib (GP Ib) is a platelet surface membrane glycoprotein composed of a heterodimer, an alpha chain and a beta chain, that is linked by disulfide bonds. The Gp Ib functions as a receptor for von Willebrand factor (VWF). The complete receptor complex includes noncovalent association of the alpha and beta subunits with platelet glycoprotein IX and platelet glycoprotein V. The binding of the GP Ib-IX-V complex to VWF facilitates initial platelet adhesion to vascular subendothelium after vascular injury, and also initiates signaling events within the platelet that lead to enhanced platelet activation, thrombosis, and hemostasis. This gene encodes the alpha subunit. Several polymorphisms and mutations have been described in this gene, some of which are the cause of Bernard-Soulier syndromes and platelet-type von Willebrand disease. [provided by RefSeq, Mar 2010]. Function: GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium. Subunit: Heterodimer composed of GP-Ib alpha and beta; disulfide linked. GP-IX is complexed with the GP-Ib heterodimer via a non covalent linkage. Interacts with FLNB. Subcellular Location: Membrane; Single-pass type I membrane protein. Post-translational modifications: Glycocalicin, which is approximately coextensive with the extracellular part of the molecule, is cleaved off by calpain during platelet lysis. DISEASE: Genetic variations in GP1BA may be a cause of susceptibility to non-arteritic anterior ischemic optic neuropathy (NAION) [MIM:258660]. NAION is an ocular disease due to ischemic injury to the optic nerve. It usually affects the optic disk and leads to visual loss and optic disk swelling of a pallid nature. Visual loss is usually sudden, or over a few days at most and is usually permanent, with some recovery possibly occurring within the first weeks or months. Patients with small disks having smaller or non-existent cups have an anatomical predisposition for non-arteritic anterior ischemic optic neuropathy. As an ischemic episode evolves, the swelling compromises circulation, with a spiral of ischemia resulting in further neuronal damage. Defects in GP1BA are a cause of Bernard-Soulier syndrome (BSS) [MIM:231200]; also known as giant platelet disease (GPD). BSS patients have unusually large platelets and have a clinical bleeding tendency. Defects in GP1BA are the cause of benign Mediterranean macrothrombocytopenia (BMM) [MIM:153670]; also known as autosomal dominant benign Bernard-Soulier syndrome. BMM is characterized by mild or no clinical symptoms, normal platelet function, and normal megakaryocyte count. Defects in GP1BA are the cause of von Willebrand disease platelet-type (PVWD) [MIM:177820]; also known as pseudo-von Willebrand disease (pseudo-vWD). This autosomal dominant bleeding disorder is caused by an increased affinity of GP-Ib for soluble vWF resulting in impaired hemostatic function due to the removal of vWF from the circulation. Similarity: Contains 7 LRR (leucine-rich) repeats. Contains 1 LRRCT domain. Contains 1 LRRNT domain. SWISS: P07359 Gene ID: 2811 Database links: Entrez Gene: 2811 Human Omim: 606672 Human SwissProt: P07359 Human Unigene: 1472 Human |
| 產品圖片 |
Sample:
Bones (Mouse) Lysate at 40 ug
Blood (Mouse) Lysate at 40 ug
Primary: Anti-CD42b (bs-2347R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 67 kD
Observed band size: 67 kD
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
